NanoenTek, Inc.
KKRX:0398604,590.00
KRW
+100.00
(+2.23%)
ISIN
KR7039860002
Return %
Stock
S&P 500
1Y
36.00
14.39
3Y
36.61
81.42
5Y
-34.43
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Chan-il Jeong
- Full Time Employees
- 141
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Seoul South Korea
- IPO Date
- Aug 16, 2000
- Website
- nanoentek.com
- Similar Companies
- Business
- NanoenTek, Inc. is a South Korea-based biotechnology and medical device company that develops, manufactures, and commercializes microfluidics- and lab-on-a-chip-based point-of-care in vitro diagnostic systems and life science research instruments. The company operates across two primary business segments: Life Science and In Vitro Diagnostics. Its core products and solutions include automated cell counters and live-cell imaging systems, comprising the EVE series of automated cell counters (EVE, EVE Plus, EVE-HT, and EVE-Auto), the JuLI series of real-time live-cell imaging and recording systems (JuLI Stage and JuLI FL), the Arthur image cytometer, and the C-Chip line of precision disposable hemocytometers; cell therapy quality control and cell analysis platforms, featuring the ADAM series of fluorescence cell counters, including the ADAM-MC2, ADAM-CellT for cell and gene therapy manufacturing processes, ADAM-CD34 for stem cell enumeration, and ADAM-rWBC for residual white blood cell analysis in blood transfusion products; point-of-care testing diagnostic platforms, anchored by the FREND System, a rapid microfluidic fluorescence immunoassay analyzer offering quantitative test cartridges for cardiac markers (Troponin I, CK-MB, and BNP), thyroid hormones (TSH and Free T4), cancer biomarkers (PSA and AFP), Vitamin D, testosterone, and infectious disease antigens; electroporation and transfection solutions, including the Neon transfection system designed for high-efficiency cellular gene delivery; and custom microfluidic plastic biochips and assay consumables manufactured through proprietary micro-machining and surface treatment technologies. NanoenTek serves clinical laboratories, hospitals, blood centers, academic research institutes, and biopharmaceutical manufacturers in more than 80 countries worldwide, supporting its international market presence through its United States subsidiary, NanoEnTek USA, Inc., located in Waltham, Massachusetts. In recent developments, the company underwent an ownership transition following the divestment of a controlling interest by SK Square, realigning its operational focus toward high-growth cell and gene therapy analytics and bioprocessing quality control. NanoenTek has expanded its commercial portfolio with advanced automated cell counting solutions, secured additional international regulatory clearances including European CE-IVDR certifications and United States FDA 510(k) clearances for its FREND and ADAM diagnostic lines, and broadened its global distribution partnerships across North America, Europe, and the Asia-Pacific region. Founded in 2000, NanoenTek, Inc. is headquartered in Seoul, South Korea.